Abstract
The use of immunotherapy as a therapeutic approach to Alzheimer's Disease (AD) is gaining rapid interest, with the primary goal of targeting abnormalities that impact neuronal viability through specific antibodies. Currently, clinical strategies focus intensively on targeting the two main pathologies associated with AD, beta-amyloid (Ab) and tau. This review examines ongoing research in the realm of tau immunotherapy, including clinical trials that demonstrate promising potential for halting AD progression. Several trials are underway, focusing on improving tau-targeted immunotherapy tools based on passive and active immunization protocols. Tau-targeted therapies have proven relevant and demonstrated safety and efficacy in both animal models and human clinical trials. Some studies have demonstrated a reduction in tau protein aggregation in animal models, highlighting a potential mechanism by which these antibodies inhibit the spread of tau protein in the extracellular space. Recent discoveries have highlighted the potential role of tau-targeting therapy with antibodies and have revealed significant promise in treating pathological tau in AD.
Reference26 articles.
1. Posner H, Curiel R, Edgar C, Hendrix S, Liu E, Loewenstein DA, et al. Outcomes assessment in clinical trials of Alzheimer’s disease and its precursors: Readying for short-term and long-term clinical trial needs. Innov Clin Neurosci. 2017; 14: 22.
2. Bakota L, Brandt R. Tau biology and tau-directed therapies for Alzheimer’s disease. Drugs. 2016; 76: 301-313.
3. Leuzy A, Chiotis K, Lemoine L, Gillberg PG, Almkvist O, Rodriguez-Vieitez E, et al. Tau PET imaging in neurodegenerative tauopathies—still a challenge. Mol Psychiatry. 2019; 24: 1112-1134.
4. Jadhav S, Avila J, Schöll M, Kovacs GG, Kövari E, Skrabana R, et al. A walk through tau therapeutic strategies. Acta Neuropathol Commun. 2019; 7: 22.
5. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM. Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem. 2011; 118: 658-667.